GlassScriptPhysician profile
Patrick M Portiz
NPI 1780011726
$1,945.21
in general payments reported to CMS, 2019-2025
12 companies · $541 in 2025
The $541 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $17.78 · 2021: $246 · 2022: $262 · 2023: $135 · 2024: $417 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,092.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,103.61 | 2019-2025 | Apretude, Cabenuva, Dovato |
| Gilead Sciences, INC. | $239.53 | 2025 | |
| Coopersurgical, INC. | $168.69 | 2019 | |
| Lilly USA, LLC | $150.96 | 2024-2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $79.15 | 2023-2025 | Wegovy, Saxenda |
| Emd Serono, INC. | $55.58 | 2024 | |
| Theratechnologies INC. | $47.29 | 2023-2024 | Trogarzo, Egrifta |
| Rxsight INC | $23.49 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Pfizer INC. | $22.34 | 2024 | |
| Exeltis, USA INC. | $20.12 | 2025 | Slynd |
| Merck Sharp & Dohme LLC | $17.78 | 2020 | |
| Currax Pharmaceuticals LLC | $16.67 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Portiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.